



Nevada PEBP

Q3 FY2024

Prepared by Client Analytics

Cynthia Eaton (cynthia.eaton@express-scripts.com)

6/04/2024



**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q3 FY24 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

CDHP Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$74.39	
Utilization	\$2.28	3.3%
Unit Cost	\$3.51	5.1%
Member Share	(\$0.37)	(0.5%)
Total Change in Plan Cost Net PMPM	\$5.41	7.8%
Previous Period - Plan Cost Net PMPM	\$68.98	

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:** Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↓ \$711k (22.3%) to current \$2.5m.
 - Plan Cost Net PMPM ↓ \$1.40 (11.0%) to current \$11.40.
 - Patient Count ↓ 5 to current count of 224.
 - Adjusted Rxs ↓ 66 to current count of 1,419.
- **Notable Drug Changes within Indication:**
 - **Revlimid:**
 - Previous ranked 1st, currently ranked 8th by Plan Cost Net.
 - Plan Cost Net ↓ \$354k (75.9%) to current \$113k.
 - Plan Cost Net PMPM ↓ \$1.35 (72.3%) to current \$.52.
 - Patient Count ↓ 2 to current count of 2.
 - Adjusted Rxs ↓ 19 to current count of 10.
 - **Ibrance:**
 - Previous ranked 2nd, currently ranked 6th by Plan Cost Net.
 - Plan Cost Net ↓ \$277k (70.5%) to current \$116k.
 - Plan Cost Net PMPM ↓ \$1.04 (66.2%) to current \$.53.
 - Patient Count ↓ 2 to current count of 2.
 - Adjusted Rxs ↓ 24 to current count of 8.

- **Lenalidomide (Generic for Revlimid):**
 - Previous ranked 12th, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$188k (177.8%) to current \$294k.
 - Plan Cost Net PMPM ↑ \$.93 (218.2%) to current \$1.35.
 - Patient Count: Remains at 3.
 - Adjusted Rxs ↑ 15 to current count of 23.

- **Vaccinations:** Previous ranked 5th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$387k (54.8%) to current \$1.1m.
 - Plan Cost Net PMPM ↑ \$2.19 (77.3%) to current \$5.01.
 - Patient Count ↓ 1,889 to current count of 5,135.
 - Adjusted Rxs ↓ 2,459 to current count of 9,677.

- **Notable Drug Changes within Indication:**
 - **Comirnaty 2023-2024 (COVID):**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$264k.
 - Plan Cost Net PMPM: New, current \$1.21.
 - Patient Count: New, current count of 1,846.
 - Adjusted Rxs: New, current count of 1,861.

 - **Spikevax 2023-2024 (COVID):**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$198k.
 - Plan Cost Net PMPM: New, current \$.91.
 - Patient Count: New, current count of 1,303.
 - Adjusted Rxs: New, current count of 1,306.

 - **Arexvy (RSV):**
 - New, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net: New, current \$156k.
 - Plan Cost Net PMPM: New, current \$.71.
 - Patient Count: New, current count of 576.
 - Adjusted Rxs: New, current count of 576.

- **Ophthalmic Conditions:** Previous ranked 21st, currently ranked 7th by Plan Cost Net.
 - Plan Cost Net ↑ \$472k (261.7%) to current \$652k.
 - Plan Cost Net PMPM ↑ \$2.27 (314.3%) to current \$2.99.
 - Patient Count ↓ 29 to current count of 285.
 - Adjusted Rxs ↑ 11 to current count of 669.

- **Notable Drug Changes within Indication:**

- **Tepezza:**

- Previous ranked 2nd, currently ranked 1st by Plan Cost Net.
- Plan Cost Net ↑ \$396k (686.5%) to current \$453k.
- Plan Cost Net PMPM ↑ \$1.85 (801.0%) to current \$2.08.
- Patient Count: Remains at 1.
- Adjusted Rxs ↑ 7 to current count of 8.

- **Eylea:**

- Previous ranked 1st, currently ranked 2nd by Plan Cost Net.
- Plan Cost Net ↑ \$54k (78.1%) to current \$123k.
- Plan Cost Net PMPM ↑ \$.29 (104.0%) to current \$.56.
- Patient Count ↑ 2 to current count of 13.
- Adjusted Rxs ↑ 32 to current count of 71.

- **Oxervate:**

- New, currently ranked 3rd by Plan Cost Net.
- Plan Cost Net: New, current \$57k.
- Plan Cost Net PMPM: New, current \$.26.
- Patient Count: New, current count of 1.
- Adjusted Rxs: New, current count of 3.

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$79.59 compared to CDHP PEBP of \$74.39.
- Peer experienced Trend of 12.0%, compared to CDHP PEBP Trend of 7.8%.

EPO Overall Trend Summaries:

EPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$167.99	
Utilization	\$7.87	5.3%
Unit Cost	\$9.11	6.1%
Member Share	\$1.67	1.1%
Total Change in Plan Cost Net PMPM	\$18.66	12.5%
Previous Period - Plan Cost Net PMPM	\$149.33	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↓ \$138k (7.4%) to current \$1.7m.
 - Plan Cost Net PMPM ↑ \$1.39 (4.3%) to current \$33.28.
 - Patient Count ↓ 13 to current count of 134.
 - Adjusted Rx's ↓ 43 to current count of 1,085.

- **Notable Drug Changes within Indication:**
 - **Humira (CF) Pen:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↓ \$225k (27.7%) to current \$588k.
 - Plan Cost Net PMPM ↓ \$2.58 (18.6%) to current \$11.32.
 - Patient Count ↓ 3 to current count of 22.
 - Adjusted Rx's ↓ 15 to current count of 172.

 - **Tavneos:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$182k.
 - Plan Cost Net PMPM: New, current \$3.51.
 - Patient Count: New, current count of 2.
 - Adjusted Rx's: New, current count of 14.

 - **Skyrizi Pen:**
 - Previous ranked 2nd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↓ \$40k (24.7%) to current \$122k.
 - Plan Cost Net PMPM ↓ \$.42 (15.1%) to current \$2.35.
 - Patient Count ↓ 1 to current count of 5.
 - Adjusted Rx's ↓ 16 to current count of 37.

- **Diabetes:** Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$135k (11.5%) to current \$1.3m.
 - Plan Cost Net PMPM ↑ \$5.16 (25.6%) to current \$25.31.
 - Patient Count ↓ 14 to current count of 608.
 - Adjusted Rx's ↓ 32 to current count of 8,503.

- **Notable Drug Changes within Indication:**
 - **Ozempic:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$108k (37.8%) to current \$393k.
 - Plan Cost Net PMPM ↑ \$2.69 (55.2%) to current \$7.57.
 - Patient Count ↑ 10 to current count of 131.
 - Adjusted Rxs ↑ 198 to current count of 870.
 - **Mounjaro:**
 - Previous ranked 4th, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$139k (136.2%) to current \$241k.
 - Plan Cost Net PMPM ↑ \$2.90 (166.1%) to current \$4.64.
 - Patient Count ↑ 29 to current count of 79.
 - Adjusted Rxs ↑ 259 to current count of 480.
 - **Trulicity:**
 - Previous ranked 2nd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↓ \$53k (27.4%) to current \$140k.
 - Plan Cost Net PMPM ↓ \$.60 (18.2%) to current \$2.70.
 - Patient Count ↓ 17 to current count of 53.
 - Adjusted Rxs ↓ 149 to current count of 327.
- **Endocrine Disorders:** Previous ranked 3rd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$245k (29.4%) to current \$1.1m.
 - Plan Cost Net PMPM ↑ \$6.52 (45.8%) to current \$20.76.
 - Patient Count ↓ 6 to current count of 27.
 - Adjusted Rxs ↓ 3 to current count of 166.
- **Notable Drug Changes within Indication:**
 - **Korlym:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$233k (30.1%) to current \$1m.
 - Plan Cost Net PMPM ↑ \$6.16 (46.6%) to current \$19.38.
 - Patient Count: Remains at 2.
 - Adjusted Rxs ↑ 6 to current count of 17.
 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO.
- Peer experienced Plan Cost Net PMPM of \$104.56 compared to PEBP EPO of \$167.99
- Peer experienced Trend of 9.8%, compared to PEBP EPO of 12.5%

PPO Overall Trend Summaries:

PPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$99.19	
Utilization	\$2.23	2.7%
Unit Cost	\$13.95	16.9%
Member Share	\$0.63	0.8%
Total Change in Plan Cost Net PMPM	\$16.80	20.4%
Previous Period - Plan Cost Net PMPM	\$82.39	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$1.1m (54.4%) to current \$3.2m.
 - Plan Cost Net PMPM ↑ \$2.52 (15.6%) to current \$18.68.
 - Patient Count ↑ 74 to current count of 256.
 - Adjusted Rx's ↑ 580 to current count of 1,914.
- **Notable Drug Changes within Indication:**
 - **Humira (CF) Pen:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$143k (23.0%) to current \$765k.
 - Plan Cost Net PMPM ↓ \$.39 (7.9%) to current \$4.51.
 - Patient Count ↑ 7 to current count of 35.
 - Adjusted Rx's ↑ 80 to current count of 241.
 - **Stelara:**
 - Previous ranked 3rd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$243k (128.9%) to current \$432k.
 - Plan Cost Net PMPM ↑ \$1.06 (71.4%) to current \$2.55.
 - Patient Count ↑ 5 to current count of 13.
 - Adjusted Rx's ↑ 40 to current count of 96.

- **Rinvoq:**
 - Previous ranked 8th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$162k (187.6%) to current \$248k.
 - Plan Cost Net PMPM ↑ \$.78 (115.3%) to current \$1.46.
 - Patient Count ↑ 8 to current count of 12.
 - Adjusted Rxs ↑ 57 to current count of 82.

- **Diabetes:** Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$1.3m (91.3%) to current \$2.6m.
 - Plan Cost Net PMPM ↑ \$4.67 (43.2%) to current \$15.46.
 - Patient Count ↑ 507 to current count of 1,410.
 - Adjusted Rxs ↑ 6,185 to current count of 17,185.

- **Notable Drug Changes within Indication:**
 - **Ozempic:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$421k (118.9%) to current \$775k.
 - Plan Cost Net PMPM ↑ \$1.78 (63.9%) to current \$4.57.
 - Patient Count ↑ 120 to current count of 285.
 - Adjusted Rxs ↑ 863 to current count of 1,730.

 - **Mounjaro:**
 - Previous ranked 4th, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$504k (494.3%) to current \$605k.
 - Plan Cost Net PMPM ↑ \$2.77 (344.9%) to current \$3.57.
 - Patient Count ↑ 134 to current count of 197.
 - Adjusted Rxs ↑ 990 to current count of 1,212.

 - **Other drug changes in this indication were not notable.**

- **Enzyme Deficiencies:** Previous ranked 6th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$771k (197.5%) to current \$1.2m.
 - Plan Cost Net PMPM ↑ \$3.77 (122.7%) to current \$6.84.
 - Patient Count ↑ 3 to current count of 6.
 - Adjusted Rxs ↑ 22 to current count of 37.

- **Notable Drug Changes within Indication:**

- **Nexviazyme:**

- Previous ranked 3rd, currently ranked 1st by Plan Cost Net.
- Plan Cost Net ↑ \$540k (1112.9%) to current \$588k.
- Plan Cost Net PMPM ↑ \$3.08 (808.1%) to current \$3.47.
- Patient Count: Remains at 1.
- Adjusted Rxs ↑ 8 to current count of 9.

- **Galafold:**

- New, currently ranked 3rd by Plan Cost Net.
- Plan Cost Net: New, current \$147k.
- Plan Cost Net PMPM: New, current \$.87.
- Patient Count: New, current count of 1.
- Adjusted Rxs: New, current count of 5.

- **Palnziq:**

- New, currently ranked 4th by Plan Cost Net.
- Plan Cost Net: New, current \$111k.
- Plan Cost Net PMPM: New, current \$.66.
- Patient Count: New, current count of 1.
- Adjusted Rxs: New, current count of 8.

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- The PEBP PPO is outperforming the peer in Plan Cost Net PMPM, however peer experienced lower trend.
- Peer experienced Plan Cost Net PMPM of \$104.56 compared to PEBP PPO of \$99.19.
- Peer experienced Trend of 9.8%, compared to PEBP PPO of 20.4%.

Total Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$95.03	
Utilization	\$2.34	2.8%
Unit Cost	\$7.83	9.4%
Member Share	\$1.16	1.4%
Total Change in Plan Cost Net PMPM	\$11.32	13.5%

Previous Period - Plan Cost Net PMPM **\$83.71**

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 9.5% in Specialty patients. This resulted in a 16.9% increase in Specialty Days of Therapy.

Overall Trend was mitigated by increased rebates of 37.5%. This produced a negative Unit Cost Trend of (4.0%) on Specialty drugs and reduced Non-Specialty Unit Cost Trend to 10.0%, combined Unit Cost Trend is 9.4%.

Member Cost contributed to Trend on Non-Specialty drugs and was flat on Specialty drugs. This is due to Drug Mix on Non-Specialty drugs, which was primary driven by utilization of more expensive brand drugs.

Key Statistics:

Nevada PEBP Total			
Description	Q3 FY24	Q3 FY23	Change
Average Members per Month	48,814	48,328	1.0%
Number of Unique patients	34,916	36,034	-3.1%
Members Utilizing the Benefit	71.5%	74.6%	-3.0
Gross Cost/Adjusted Rx	\$100.86	\$91.68	10.0%
Plan Spend	\$63,879,300	\$52,503,413	21.7%
Rebates (estimated)	\$22,129,313	\$16,094,911	37.5%
Plan Cost Net	\$41,749,987	\$36,408,502	14.7%
Plan Cost Net PMPM	\$95.03	\$83.71	13.5%
Non-Specialty Plan Cost Net PMPM	\$44.09	\$38.11	15.7%
Specialty Plan Cost Net PMPM	\$50.94	\$45.60	11.7%
Generic Fill Rate	86.4%	85.1%	1.2
90 Day Utilization	60.4%	61.7%	-1.3
Retail - Maintenance 90 Utilization	28.3%	28.8%	-0.5
Home Delivery Utilization	32.1%	32.8%	-0.7
Member Cost Net %	25.4%	26.3%	-0.9

END OF REPORT